First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men.

First published in Journal of Thrombosis and Haemostasis on 2022 May.
J Thromb Haemost. 2022 May 1. doi: 10.1111/jth.15744. Online ahead of print.

Authors: Nowotny B, Thomas D, Schwers S, Wiegmann S, Prange W, Yassen A, Boxnick S

Download full article as Pdf file:

Pdf File

REACHING OUT IS EASY AND FAST – LET’S TALK

Prof. Dr. Thomas Forst

Chairman of the Executive Board
located at CRS Mannheim

LET’S TALK SCIENCE

+49 621 150 45 – 0

Dr. Marc Hetzel

VP & Head of Business Development
located at CRS Management

LET’S TALK BUSINESS

+49 621 150 45 – 0

First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men.

Read more

REACHING OUT IS EASY AND FAST – LET’S TALK

You May Also Like

Bioequivalence of macitentan and tadalafil given as fixed-dose combination or single-component tablets in healthy subjects.

Midazolam microdosing applied in early clinical development for drug-drug interaction assessment.

The effects of vilaprisan on the pharmacodynamics and pharmacokinetics of a combined oral contraceptive – A randomized controlled trial.